Shiva Vaheb Hosseinabadi | Genetics and Bioinformatics | Young Scientist Award

Published on by Plant Scientist

Ms. Shiva Vaheb Hosseinabadi | Genetics and Bioinformatics | Young Scientist Award

Zist Fanavari Novin biotechnology Institute | Iran

Dr. Shiva Vaheb Hosseinabadi is a molecular and cellular biologist and researcher currently serving as a molecular-techniques instructor and research supervisor at Zist Fanavari Novin Biotechnology Institute (since 2024). She earned her M.Sc. in Cellular and Molecular Sciences from Razi University (2019) and a B.Sc. in Molecular and Cellular Biology-Genetics from Islamic Azad University of Falavarjan. Her research and technical expertise span gene expression analysis, neurogenetics, cancer genomics, mutation analysis, next-generation sequencing (NGS), and bioinformatics. She has contributed to over a dozen peer-reviewed research articles — including studies on microRNA regulation in Parkinson’s disease models, co-frameshift mutations in acute myeloid leukemia, neurotoxicity attenuation via miR-361-5p, and exploration of lncRNA–miRNA networks in various cancers — with total publications exceeding 15 and cumulative citations in the low hundreds [exact citation count varies by database]. Dr. Hosseinabadi is proficient in molecular lab techniques (PCR/qPCR, cell culture, NGS), data analysis (R, Python, SPSS), and bioinformatics workflows. Her dual role as scientist and educator allows her to translate cutting-edge genetic research into practical training and application, contributing to advances in personalized medicine, neurogenetics, cancer biomarker discovery, and genomic diagnostics. Her ongoing work, including a 2025 book on cancer diagnostics and drug-resistance, underscores her commitment to bridging research and clinical translation.

Profile: Google Scholar

Featured Publications

Hosseinabadi, S. V., Tahamtan, H., Esfahani, M. M., Ghaedi-Heidari, R., Hashemi, M. S., Peymani, M., Sisakhtnezhad, S., Fahimi, H., & Ghaedi, K. (2025). Upregulation of miR-361-5p attenuates MPP+-induced neurotoxicity in dopaminergic SH-SY5Y cells as a Parkinson’s disease model. Journal of Biological Chemistry.

Roshani, H. R., Nasiri, A., Sattari, A., Rasaei, S., Karimian, P., Jannesari, F., … Hosseinabadi, S. V., & Azadeh, M. (2025). Uncovering an ADH1C–lncRNA regulatory axis linking alcohol metabolism to diagnostic potential in colorectal, breast, and gastric cancers.

Ghasroldasht, M. M., Hosseinabadi, S. V., Ebrahimi Askari, R., & Lotfalipour, R. (2025). Novel co-frameshift mutations in N- and C-terminal regions of CEBPA in acute myeloid leukemia: A case report. Cancer Genetics.

Esfahani, M. M., Mostashfi, M., Hosseinabadi, S. V., Hashemi, M. S., Peymani, M., & Nasr-Esfahani, M. H., et al. (2024). Unveiling the regulatory role of miR-101-3p on ZNF746 in a Parkinson’s disease cell model: Implications for therapeutic targeting. Neuroscience Research.

Mansoureh Azadeh | Genetics and Bioinformatics | Excellence in Research award

Published on by Plant Scientist

Prof. Dr. Mansoureh Azadeh | Genetics and Bioinformatics | Excellence in Research award

Zist Fanavari Novin Biotechnology Institute | Iran

Dr. Mansoureh Azadeh Jouneghani is a seasoned molecular and cellular biologist, currently CEO of PreventiGene — a startup she launched in 2023 to promote cancer prevention through advanced genetic testing. With a Ph.D. in Cellular and Molecular Biology, she also founded and leads Zist Fanavari Novin Biotechnology Institute since 2011, and has taught at the university level for 20 semesters at Azad University. Over her career she has led and managed substantial research initiatives in cancer genomics, drug-resistance mechanisms in cancer (especially breast cancer), genomic biomarkers for multiple sclerosis and cardiovascular disease, athlete genomics for performance and injury prevention, and personalized medicine. She is proficient in gene expression analysis, RNA sequencing, CRISPR, bioinformatics, and high-throughput data analytics, and has supervised training in numerous molecular-biology lab techniques (PCR, qRT-PCR, ELISA, cell culture, Western blot). Her research output includes over 100 publications, covering peer-reviewed articles, conference papers, and laboratory-technique handbooks; her work has contributed significantly to genomic medicine and translational biotechnology. As a leader and educator she bridges academia, industry, and clinical research — advancing personalized medicine, improving genomic diagnostics, and fostering vocational biotech education. Her dedication continues to contribute to better health outcomes, scientific innovation, and capacity-building in biotechnology.

Profile: Google Scholar

Featured Publications

Azadeh, M., Salehzadeh, A., Ghaedi, K., & Talesh Sasani, S. (2022). NEAT1 can be a diagnostic biomarker in breast cancer and gastric cancer patients by targeting XIST, hsa-miR-612, and MTRNR2L8: Integrated RNA targetome… Genes and Environment.

Fattahi Dolatabadi, N., Dehghani, A., Shahand, E., Yazdanshenas, M., et al. (2020). The interaction between MALAT1 target, miR-143-3p, and RALGAPA2 is affected by functional SNP rs3827693 in breast cancer.

Adami, B., Tabatabaeian, H., Ghaedi, K., Talebi, A., Azadeh, M., & Dehdashtian, E. (2019). miR-146a is deregulated in gastric cancer. Journal of Cancer Research and Therapeutics.

Assad Samani, L., Javadirad, S. M., Parsafar, S., Tabatabaeian, H., Ghaedi, K., et al. (2019). TP53 rs1625895 is related to breast cancer incidence and early death in Iranian population. Indian Journal of Clinical Biochemistry.

Dehghan, Z., Sadeghi, S., Tabatabaeian, H., Ghaedi, K., Azadeh, M., Fazilati, M., et al. (2017). *ESR1 single nucleotide polymorphism rs1062577 (c.3804T>A) alters the susceptibility of breast cancer risk in Iranian population. Gene.